ArticleIn vivo (Athens, Greece)
Activin A/Follistatin Axis in Airway Diseases and its Association With Recurrent Exacerbations.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory-metabolic alterations in asthma-COPD overlap compared with COPD: evidence from NHANES and a hospital-based cohort.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimChronic airway diseases, including chronic obstructive pulmonary disease (COPD), asthma, and asthma COPD overlap (ACO), are characterized by complex inflammatory processes in which Activin A-a key member of the TGF-β superfamily-is implicated. Although its role in the stable state of these diseases has been extensively studied, data regarding its involvement during exacerbations remain limited. Our objective was to investigate the dynamics of Activin A in sputum and serum during acute exacerbations and subsequent convalescence in patients with chronic airway diseases. PATIENTS AND
methodsIn this prospective study, 53 patients with asthma, COPD, and ACO, aged 14 years and older were recruited upon hospitalization for an acute exacerbation. Sputum and peripheral blood samples were collected at admission, hospital discharge, one month, and four months post-exacerbation. Protein levels of Activin A were quantified by ELISA were compared among the patient groups and the kinetics of Activin A expression following exacerbation events were examined.
resultsBaseline Activin A levels were comparable across the patient groups. However, during exacerbations, sputum Activin A levels increased markedly and subsequently declined during convalescence, while serum levels exhibited an inverse pattern-being lower during exacerbations and rising during stable periods. Notably, COPD patients with recurrent exacerbations maintained persistently elevated sputum Activin A levels throughout the study period, suggesting that sustained local inflammation may predispose these patients to frequent exacerbations.
conclusionThese findings reveal a compartment-specific regulation of Activin A in chronic airway diseases, underscoring its potential as a biomarker for disease activity and exacerbation risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.